CLAIMS

1. Use of a PLA2 inhibitor in the manufacture of a medicament for treating the effects of snake envenomation in a subject in need, wherein the PLA2 inhibitor is varespladib, methylvarespladib, a pharmaceutically acceptable salt thereof or a mixture thereof.

2. The use according to claim 1 wherein said PLA2 inhibitor is varespladib, methylvarespladib or a pharmaceutically acceptable salt thereof.

3. The use of claim 1 or 2 wherein the PLA2 inhibitor is used in combination with a therapeutically effective amount of at least one agent selected from the group consisting of a metalloproteinase inhibitor, a serine protease inhibitor or a mixture thereof in a single medicament with said PLA2 inhibitor or in more than one medicament.

4. The use according to any of claims 1-3 wherein the medicament is used in combination with a therapeutically effective amount of an antivenom either separately from the PLA2 inhibitor or the PLA2 inhibitor and the metalloproteinase inhibitor and/or the serine protease inhibitor or in a single medicament with the PLA2 inhibitor or the PLA2 inhibitor and the metalloproteinase inhibitor and/or the serine protease inhibitor.

5. The use according to any one of claims 1-4 wherein said medicament is used in combination with a therapeutically effect amount of at least one agent selected from the group consisting of a spreading factor inhibitor, an NMDA receptor antagonist, an acetylcholinesterase inhibitor, an L-aminooxidase inhibitor and a hyaluronidase inhibitor, wherein the medicament or the

medicament and the metalloproteinase inhibitor and/or the serine proteinase inhibitor and the agent(s) are used separately or in a mixture.

6. The use according to claim 3 or 4, wherein the medicament is formulated for injection, intranasal, ocular, oral, topical or inhalation administration and optionally comprises an acetylcholinesterase inhibitor or an AChEI.

7. The use according to any of claims 1-6 wherein the medicament is used along with an acetylcholinesterase inhibitor (AChEI) or an AChEI combination either separately or in a mixture.

8. The use according to claim 1 or 2 wherein the PLA2 inhibitor is varespladib and/or methylvarespladib and said medicament is used along with at least one agent selected from the group consisting of prinomastat, marimastat, vorinostat, cefixime, doxycycline and batimastat and an AChEI.

9. The use according any of claims 1-8 wherein said medicament is used with neostigmine, further in combination with a muscarinic acetyl choline receptor (mAChR) inhibitor, optionally wherein said medicament, said neostigmine and said mAChR inhibitor are used as the sole active agents.

10. The use according to any of claims 3-9,

(i) wherein the metalloproteinase inhibitor is selected from the group consisting of prinomastat, BB-94 (marimastat), BB-2516 (batimastat), vorinostat, ilomastat, doxycycline, tanomastat and mixtures thereof alone or in combination with TAPI-2, TAPI-1, EGTA, EDTA, phosphoramadon, TAPI-0, Luteolin, alendronate, tanomastat, collagenase inhibitor 1, Ro-32-3555, lactobionic acid, ophenantroline, ecotin, 4-epi-chlortetracycline, tetracycline, doxycycline n-dansyl-d-phenylalanine, 20[R]ginsenosideRh2, pro-leu-gly-hydroxymate,

gm6001, actinonin, arp-100, MMP9 inhibitor I, MMP2 inhibitor I, SB-3CT, Thiorphan (DL), 4-epi-demeclocycline, zinc methacrylate, funalenone, naturally derived or synthetic short peptide-inhibitor of snake venom metalloproteinase and pharmaceutically acceptable salts and mixtures thereof, or

(ii) wherein the metalloproteinase inhibitor is prinomastat, marimastat or vorinostat are used at a concentration of between about 1 to about 500 μM; and/or (2) in an amount of between about 0.0001 to about 100 g, or

(iii) wherein the serine protease inhibitor is selected from the group consisting of gabexate, camostat or camostate, nafamostat, aprotinin, leupeptin, antithrombin (AT), alpha-1 antitrypsin (α1-antitrypsin (A1AT)), AEBSF (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride), PMSF (phenylmethanesulfonylfluoride or phenylmethylsulfonyl fluoride), protein C inhibitor (PCI, SERPINA5), protein Z-dependent protease inhibitor, methoxy arachidonyl fluorophosphonate (MAFP), myeloid and erythroid nuclear termination stage-specific protein (MENT), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (placental PAI), protease-nexin-1 (PN-1), antithrombin III, collagen, phosphatidylethanolamine-binding protein, neuroserpin, α2-antiplasmin, serine protease inhibitor 3, and murinoglobin I, or a pharmaceutically acceptable salt or mixture thereof.

11. The use according to any of claims 1-9 wherein the PLA2 inhibitor is varespladib or a mixture of varespladib and methylvarespladib which is/are combined with at least one additional PLA2 inhibitor selected from the group consisting of indoxam, methylindoxam, Suramin, AIPLAI (Azadirachta indica PLA2 inhibitor), BMS-181162, LY311727, ARL-67974, FPL67047, SB-

203347, Ro-23-9358, YM-26734, YM 26567, IS-741, MJ33, flunixin, Effipladib, Way 196025, Ecopladib, Giripladib, Variabilin, SB 203347, PAF-AH, Darapladib, phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylglycerol (PG), mixtures thereof and their pharmaceutically acceptable salts or alternative salts; or wherein when said PLA2 inhibitor is a mixture of varespladib and methylvarespladib, wherein said varespladib and said methylvarespladib are used each at a concentration of between 0.1, 1, 10, 100, 110, 120, 230, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, and 500 to 1250, 750 to 1250, or 801 to 1000 μM; and/or (2) in an amount of between 0.0001, 0.001, 0.01, 0.1, 1, 10 or 100 and 1,000 mg.

12. The use according to any of claims 1-3, 6-8 or 10 wherein said medicament is used in combination with an antivenom.

13. The use according to claim 12 wherein said antivenom is freeze-dried Habu Antivenom or freeze-dried Mamushi Antivenom of equine origin.

14. The use according to any of claims 1-12 wherein said PLA2 inhibitor is varespladib.

15. The use according to any of claims 1-12 wherein said inhibitor is methylvarespladib.

16. The use according to claim 1 wherein said inhibitor is a mixture of varespladib and methylvarespladib.